MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
Key Highlights
- ➤SKNY-1 significantly reduced body weight and fat mass versus vehicle controls in obese mice
- ➤SKNY-1 showed no significant lean-mass loss versus controls at Day 14
- ➤Semaglutide-treated mice showed significant lean-mass loss versus vehicle controls
- ➤SKNY-1 mice had limited weight regain after treatment, unlike semaglutide mice
- ➤MIRA is advancing longer-term preclinical studies and IND-enabling development for SKNY-1
Expert Statements
Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals
“Obesity represents one of the largest and fastest-growing opportunities in healthcare, with the potential for multiple multibillion-dollar therapies.”
Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals
“We believe the future of obesity treatment will extend beyond a single class of drugs.”
Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals
“Patients have different needs, and there is tremendous opportunity for innovative therapies that work through distinct mechanisms and offer favorable profiles for long-term weight management.”
Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals
“What makes SKNY-1 particularly exciting is that our findings point toward a potentially differentiated metabolic approach, with encouraging signals regarding body composition and weight maintenance following treatment discontinuation.”
Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals
“We believe these characteristics could become important advantages as we continue advancing SKNY-1, positioning it as a potentially valuable asset within our pipeline and an opportunity to participate in this significant global market.”
Dr. Itzchak Angel, Chief Scientific Advisor of MIRA Pharmaceuticals
“One of the most intriguing findings from this pilot study is that SKNY-1 produced significant weight reduction without a statistically significant decrease in food consumption.”
Dr. Itzchak Angel, Chief Scientific Advisor of MIRA Pharmaceuticals
“The contrasting observations in lean-mass outcomes and weight regain following treatment discontinuation compared with the semaglutide reference group are also scientifically interesting.”
Dr. Itzchak Angel, Chief Scientific Advisor of MIRA Pharmaceuticals
“Together, these findings raise the possibility that SKNY-1 may influence how the body utilizes energy, potentially offering a differentiated metabolic approach to weight management.”
Dr. Itzchak Angel, Chief Scientific Advisor of MIRA Pharmaceuticals
“These results further expand and confirm previous studies, which have demonstrated increased energy expenditure without changes in food intake.”
Dr. Itzchak Angel, Chief Scientific Advisor of MIRA Pharmaceuticals
“Our next study will investigate this hypothesis more directly through measurements of energy expenditure and other metabolic parameters, while further characterizing SKNY-1's effects on body composition and weight regulation.”
SKNY-1's Weight Reduction Without Significant Changes in Food Consumption Suggests a Potential Role for Energy Expenditure, Contrasting With Semaglutide's Initial Food-Intake Suppression and Significant Post-Treatment Increase
MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral therapeutics, today announced initial positive proof-of-concept results from an exploratory pilot study evaluating SKNY-1, its investigational oral drug candidate for obesity and metabolic disorders.
Get started
Create a free account to read the full story.